scholarly journals A Novel Cell-Based, High-Content Assay for Phosphorylation of Lats2 by Aurora A

2011 ◽  
Vol 16 (8) ◽  
pp. 925-931 ◽  
Author(s):  
Amy Emery ◽  
David A. Sorrell ◽  
Stacy Lawrence ◽  
Emma Easthope ◽  
Mark Stockdale ◽  
...  
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
Kinase Activity ◽  
High Content Screening ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Assay Performance ◽  
A Cell ◽  
Significant Addition ◽  
Specific Inhibitors

Aurora A kinase is a key regulator of mitosis, which is upregulated in several human cancers, making it a potential target for anticancer therapeutics. Consequently, robust medium- to high-throughput cell-based assays to measure Aurora A kinase activity are critical for the development of small-molecule inhibitors. Here the authors compare measurement of the phosphorylation of two Aurora A substrates previously used in high-content screening Aurora A assays, Aurora A itself and TACC3, with a novel substrate Lats2. Using antibodies directed against phosphorylated forms of Aurora A (pThr288), P-TACC3 (pSer558), and P-Lats2 (pSer83), the authors investigate their suitability in parallel for development of a cell-based assay using several reference Aurora inhibitors: MLN8054, VX680, and AZD1152-HQPA. They validate a combined assay of target-specific phosphorylation of Lats2 at the centrosome and an increase in mitotic index as a measure of Aurora A activity. The assay is both sensitive and robust and has acceptable assay performance for high-throughput screening or potency estimation from concentration–response assays. It has the advantage that it can be carried out using a commercially available monoclonal antibody against phospho-Lats2 and the widely available Cellomics ArrayScan HCS reader and thus represents a significant addition to the tools available for the identification of Aurora A specific inhibitors.

A Cell-based High-throughput Screening Approach for the Discovery of New Inhibitors of the Influenza H5N1 Virus

2008 ◽  
Vol 78 (2) ◽  
pp. A48
Author(s):  
William Severson ◽  
Joseph Maddry ◽  
Xi Chen ◽  
Subramaniam Ananthan ◽  
Adrian Poffenberger ◽  
...  
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
H5n1 Virus ◽  
Screening Approach ◽  
A Cell ◽  
Influenza H5n1

scholarly journals Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening

2020 ◽  
Author(s):  
Yan Li ◽  
Jinyong Zhang ◽  
Ning Wang ◽  
Haibo Li ◽  
Yun Shi ◽  
...  
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
Binding Capacity ◽  
Effective Means ◽  
Clinical Applications ◽  
Therapeutic Drugs ◽  
Main Protease ◽  
Novel Coronavirus ◽  
Clinical Drug ◽  
Specific Inhibitors

Abstract2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of the outbreak of pneumonia first detected in Wuhan, China. Investigations on the transmissibility, severity, and other features associated with this virus are ongoing. Currently, there is no vaccine or therapeutic antibody to prevent the infection, and more time is required to develop an effective immune strategy against the pathogen. In contrast, specific inhibitors targeting the key protease involved in replication and proliferation of the virus are the most effective means to alleviate the epidemic. The main protease of SARS-CoV is essential for the life cycle of the virus, which showed 96.1% of similarity with the main proteaseof 2019-nCoV, is considered to be an attractive target for drug development. In this study, we have identified 4 small molecular drugs with high binding capacity with SARS-CoV main protease by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of 2019-nCoV.

scholarly journals A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH

2019 ◽  
Vol 294 (29) ◽  
pp. 11259-11275 ◽  
Author(s):  
Mitsuharu Ueda ◽  
Masamitsu Okada ◽  
Mineyuki Mizuguchi ◽  
Barbara Kluve-Beckerman ◽  
Kyosuke Kanenawa ◽  
...  
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
Amyloid Fibril ◽  
Screening Method ◽  
Fibril Formation ◽  
Neutral Ph ◽  
Amyloid Fibril Formation ◽  
A Cell

scholarly journals Targeting Quorum Sensing: High-Throughput Screening to Identify Novel LsrK Inhibitors

2019 ◽  
Vol 20 (12) ◽  
pp. 3112 ◽  
Author(s):  
Viviana Gatta ◽  
Polina Ilina ◽  
Alison Porter ◽  
Stuart McElroy ◽  
Päivi Tammela
Keyword(s):  
Quorum Sensing ◽  
High Throughput ◽  
High Throughput Screening ◽  
Enteric Bacteria ◽  
New Class ◽  
Bacterial Pathogenicity ◽  
Autoinducer 2 ◽  
A Cell ◽  
The Moment ◽  
Antivirulence Agents

Since quorum sensing (QS) is linked to the establishment of bacterial infection, its inactivation represents one of the newest strategies to fight bacterial pathogens. LsrK is a kinase playing a key role in the processing of autoinducer-2 (AI-2), a quorum-sensing mediator in gut enteric bacteria. Inhibition of LsrK might thus impair the quorum-sensing cascade and consequently reduce bacterial pathogenicity. Aiming for the development of a target-based assay for the discovery of LsrK inhibitors, we evaluated different assay set-ups based on ATP detection and optimized an automation-compatible method for the high-throughput screening of chemical libraries. The assay was then used to perform the screening of a 2000-compound library, which provided 12 active compounds with an IC50 ≤ 10 µM confirming the effectiveness and sensitivity of our assay. Follow-up studies on the positive hits led to the identification of two compounds, harpagoside and rosolic acid, active in a cell-based AI-2 QS interference assay, which are at the moment the most promising candidates for the development of a new class of antivirulence agents based on LsrK inhibition.

scholarly journals Aurora A kinase activity is required for localization of TACC3/ch-TOG/clathrin inter-microtubule bridges

2011 ◽  
Vol 4 (4) ◽  
pp. 409-412 ◽  
Author(s):  
Liam P. Cheeseman ◽  
Daniel G. Booth ◽  
Fiona E. Hood ◽  
Ian A. Prior ◽  
Stephen J. Royle
Keyword(s):  
Kinase Activity ◽  
Aurora A Kinase ◽  
Aurora A

scholarly journals Human Immunodeficiency Virus Type 1 Latency Model for High-Throughput Screening

2005 ◽  
Vol 49 (12) ◽  
pp. 5185-5188 ◽  
Author(s):  
Sofiya Micheva-Viteva ◽  
Annmarie L. Pacchia ◽  
Yacov Ron ◽  
Stuart W. Peltz ◽  
Joseph P. Dougherty
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
High Throughput ◽  
High Throughput Screening ◽  
Immunodeficiency Virus ◽  
Latently Infected ◽  
A Cell ◽  
Hiv 1

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.

scholarly journals A Cell-Based Renilla Luminescence Reporter Plasmid Assay for High-Throughput Screening to Identify Novel FDA-Approved Drug Inhibitors of HPV-16 Infection

2019 ◽  
Vol 25 (1) ◽  
pp. 79-86
Author(s):  
Tara Walhart ◽  
Erin Isaacson-Wechsler ◽  
Kean-Hooi Ang ◽  
Michelle Arkin ◽  
Sharof Tugizov ◽  
...  
Keyword(s):  
Anal Cancer ◽  
High Throughput ◽  
High Throughput Screening ◽  
Hpv Infection ◽  
Reporter Expression ◽  
Expression Plasmid ◽  
Hpv 16 ◽  
Public Health Burden ◽  
A Cell ◽  
Approved Drugs

Like cervical cancer, anal cancer is caused by human papillomavirus (HPV). HPV is the most common sexually transmitted agent and is found in the anal canal of almost all HIV-positive men who have sex with men (MSM). Rates of HPV anal cancer are disproportionately higher in this population. Although the nanovalent HPV vaccine is efficacious in protecting against oncogenic HPV types, a substantial proportion of MSM remains unvaccinated and anal HPV infection continues to be an important public health burden. Therefore, it is important to identify strategies to prevent HPV infection. We report on two promising and interlinked strategies: (1) the development of a cell-based Renilla luminescence reporter assay using HPV-16 pseudovirions that encapsidate SV40-driven Renilla luminescence reporter expression plasmid and (2) use of this assay for high-throughput screening (HTS) of FDA- and internationally approved drugs to identify those that could be repurposed to prevent HPV infection. We conducted a screen of 1906 drugs. The assay was valid with a Z′ of 0.67 ± 0.04, percent coefficient of variance of 10.0, and signal-to-background noise window of 424.0 ± 8.0. Five drugs were chosen for further analyses based on selection parameters of ≥77.0% infection of HPV-16 pseudovirion-driven Renilla expression with <20.0% cytotoxicity. Of these, the antifungal pentamidine and a gamma-amino butyric acid receptor agonist securinine exhibited ≥90.0% infection with <10.0% cytotoxicity. This luminescent cell-based reporter expression plasmid assay for HTS is a valid method to identify FDA- and internationally approved drugs with the potential to be repurposed into prevention modalities for HPV infection.

scholarly journals A cell-based high-throughput screening assay for radiation susceptibility using automated cell counting

2015 ◽  
Vol 10 (1) ◽  
pp. 55 ◽  
Author(s):  
Jasmina Hodzic ◽  
Ilse Dingjan ◽  
Mariëlle Maas ◽  
Ida H van der Meulen-Muileman ◽  
Renee X de Menezes ◽  
...  
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
Cell Counting ◽  
Screening Assay ◽  
Automated Cell Counting ◽  
High Throughput Screening Assay ◽  
A Cell
Sign in / Sign up

Export Citation Format

Share Document